Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;13(Suppl 4):23-30.
doi: 10.6004/jadpro.2022.13.5.12. Epub 2022 Jul 28.

A Focus on Special Populations in Relapsed Multiple Myeloma

Affiliations

A Focus on Special Populations in Relapsed Multiple Myeloma

Mary Steinbach et al. J Adv Pract Oncol. 2022 Jul.

Abstract

The overall care of patients with multiple myeloma can present similar challenges. However, disparities in health care require that providers consider each individual's unique circumstances. Disparities based on ethnic/racial group, religion, socioeconomic status, age, sexual orientation or gender identity, or other characteristics can lead to patients receiving less than optimal care and therefore poorer outcomes. Patients who have received more than two lines of therapy can acquire new genetic changes, accelerated cadence of relapse, and suffer from disease sequelae such as pain from prior or ongoing skeletal fractures, recurrent infections, and progressive decline in organ function. Numerous treatment options remain for patients in their first three relapses. Well-designed clinical trials with newer drugs are preferred. Clinicians should discuss clinical trial options and availability with all patients in spite of disparities that may exist. Patients facing disparities are at risk for suboptimal care and should be closely monitored and provided appropriate resources. Continued attention to disease and organ surveillance are critical throughout the course of the disease.

PubMed Disclaimer

Conflict of interest statement

Dr. Steinbach has served on speakers bureaus for GSK and Karyopharm. Ms. Colson has served as a consultant for Bristol Myers Squibb, Oncopeptides, and Sanofi. Dr. Faiman has served as a consultant for Bristol Myers Squibb, GSK, Janssen, Karyopharm, Legend Biotech, Oncopeptides, Sanofi, and Takeda.

References

    1. Ailawadhi, S., Jacobus, S., Sexton, R., Stewart, A. K., Dispenzieri, A., Hussein, M. A.,…Rajkumar, S. V. (2018). Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer Journal, 8(7). 10.1038/s41408-018-0102-7 - DOI - PMC - PubMed
    1. Chakraborty, R., Muchtar, E., Kumar, S., Buadi, F. K., Dingli, D., Dispenzieri, A.,…Gertz, M. A. (2016). The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 52(1), 34–40. 10.1038/bmt.2016.214 - DOI - PubMed
    1. Farooq, A. V., Degli Esposti, S., Popat, R., Thulasi, P., Lonial, S., Nooka, A. K.,…Colby, K. (2020). Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmology and Therapy, 9(4), 889–911. 10.1007/s40123-020-00280-8 - DOI - PMC - PubMed
    1. GSK. (2020). Blenrep (belantamab mafodotin-blmf) package insert. https://gskpro.com/content/dam/global/hcp-portal/en_US/Prescribing_Infor...
    1. Guerra, C. E., Sallee, V., Hwang, W.-T., Bryant, B., Washington, A. L., Takvorian, S. U.,…Nathanson, K. L. (2021). Accrual of Black participants to cancer clinical trials following a five-year prospective initiative of community outreach and engagement. Journal of Clinical Oncology, 39(15_suppl), 100. 10.1200/JCO.2021.39.15_suppl.100 - DOI - PubMed

LinkOut - more resources